Key result
Atorvastatin treatment for 3 months in patients with arterial hypertension improved L-arginine cerebrovascular reactivity (from 12.5% to 19.5%) more than systemic flow-mediated dilatation.
Why the study?
Does atorvastatin improve cerebral and systemic endothelial function in patients with arterial hypertension?
Observational (n=50)
Does atorvastatin improve cerebral and systemic endothelial function in patients with arterial hypertension?
Atorvastatin treatment in patients with arterial hypertension improves cerebral endothelial function more prominently than systemic endothelial function.
Atorvastatin may preferentially enhance cerebrovascular endothelial function in hypertension; hypothesis-generating and should not yet change practice.
BACKGROUND: The pleiotropic effects of statins on the endothelial function are well recognized. However, the effect of statins might not be equally pronounced in the cerebral and systemic circulation. We compared cerebral and systemic endothelial function by L-arginine cerebrovascular reactivity and flow-mediated dilatation (FMD), respectively, in patients with arterial hypertension (AH) and healthy controls before and after atorvastatin treatment. METHOD: L-arginine reactivity and FMD were measured in patients with AH (29 patients, aged 61.1 +/- 6.2 years) and 21 healthy controls. The mean arterial velocity (v(m)) in both middle cerebral arteries was measured by transcranial Doppler sonography before, during, and after a 30-min intravenous infusion of L-arginine. FMD of the brachial artery after hyperemia was determined. The measurements were repeated after 3 months of treatment with atorvastatin. RESULTS: L-arginine reactivity and FMD were decreased in patients with AH (12.5 +/- 8.7%; 2.7 +/- 5.0 %) compared with controls (21.3 +/- 10.9%; 8.5 +/- 5.9%) (P < 0.01). After atorvastatin treatment, L-arginine reactivity and FMD improved in patients with AH (19.5 +/- 10.6%; 4.6 +/- 4.1%) compared with the controls (20.2 +/- 10.2%; 9.7 +/- 3.9%). The use of statin restored the cerebral circulation reactivity, while there was little change in the systemic circulation measured by FMD. CONCLUSION: The decreased L-arginine reactivity and FMD were found to improve after atorvastatin treatment in patients with AH, but the results suggest that statin therapy improved cerebral more than systemic endothelial function.
No takes yet. Share an insight, caveat, or question.
Oblak et al. (2008) conducted an observational in Arterial hypertension (n=50). Atorvastatin vs. Healthy controls was evaluated on L-arginine cerebrovascular reactivity and flow-mediated dilatation (FMD). Atorvastatin treatment for 3 months in patients with arterial hypertension improved L-arginine cerebrovascular reactivity (from 12.5% to 19.5%) more than systemic flow-mediated dilatation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: